IFNA1 and systemic lupus erythematosus: Despite this, none of them contain type I IFN (e.g., IFN-α or IFN-β), although its substantial role has been highlighted in several ADs, including SLE, where multiple approved or developing therapies are designed to block the type I IFN-inducible pathway of inflammation.